Stock comparison
Haemonetics
Organon &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
OGN
Organon &
Market cap
$3.53B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | OGN | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 57C | HAE |
| Benjamin Graham | 85A | 78B | HAE |
| Philip Fisher | 60C | 38D | HAE |
| Peter Lynch | 54C | 27F | HAE |
| Joel Greenblatt | 31F | 21F | HAE |
| Charlie Munger | 54D | 48D | HAE |
| Terry Smith | 55D | 46D | HAE |
Side-by-side metrics
| Metric | HAE | OGN |
|---|---|---|
| Market cap | $2.98B | $3.53B |
| P/E (TTM) | 24.8x | 14.2x |
| EV/EBIT | 14.1x | 8.5x |
| ROIC (TTM) | 8.37% | 5.16% |
| Gross margin | 55.74% | 53.11% |
| Net margin | 7.29% | 3.99% |
| Revenue CAGR 5y | 7.65% | -0.35% |
| EPS CAGR 5y | 24.62% | -39.38% |
| Debt / Equity | 1.5x | 9.5x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -39.38%+163%
- Revenue CAGR 5y7.65%vs -0.35%+105%
- Debt / Equity1.5xvs 9.5x+84%
- Net margin7.29%vs 3.99%+45%
OGN leads on
- Dividend yield0.6%vs 0.0%+100%
- P/E (TTM)14.2xvs 24.8x+43%
- EV/EBIT8.5xvs 14.1x+39%
- Market cap$3.53Bvs $2.98B+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.